ANTI-IGF-I RECEPTOR ANTIBODY

Number of patents in Portfolio can not be more than 2000

United States of America Patent

SERIAL NO

12251884

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IMMUNOGEN INC830 WINTER STREET WALTHAM MA 02451

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dagdigian, Nancy E Acton , US 9 231
SINGH, Rajeeva Cambridge , US 33 735
Tavares, Daniel J Natick , US 23 321

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation